Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2020 Financial Results and Recent Corporate Developments on March 1, 2021
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) will disclose its fourth quarter and full-year 2020 financial results on March 1, 2021, after the Nasdaq closes. A conference call will follow at 4:30 p.m. E.T. to discuss the results and provide a corporate update. Investors can access the call at (844) 534-7313 for domestic or (574) 990-1451 for international, using passcode 9672289. Sarepta specializes in precision genetic medicine, particularly in DMD and gene therapies for various rare diseases, with over 40 programs in development.
- Sarepta has over 40 programs in various stages of development, indicating robust research activity.
- The company leads in precision genetic medicine for rare diseases, particularly in Duchenne muscular dystrophy.
- None.
CAMBRIDGE, Mass., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report fourth quarter and full-year 2020 financial results after the Nasdaq Global Market closes on Monday, March 1, 2021. Subsequently, at 4:30 p.m. E.T., the Company will host a conference call to discuss its fourth quarter and full year 2020 financial results and to provide a corporate update.
The conference call may be accessed by dialing (844) 534-7313 for domestic callers and (574) 990-1451 for international callers. The passcode for the call is 9672289. Please specify to the operator that you would like to join the "Sarepta Fourth Quarter and Full-Year 2020 Earnings Call." The conference call will be webcast live under the investor relations section of Sarepta's website at www.sarepta.com and will be archived there following the call for 90 days. Please connect to Sarepta's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.
About Sarepta Therapeutics
At Sarepta, we are leading a revolution in precision genetic medicine and every day is an opportunity to change the lives of people living with rare disease. The Company has built an impressive position in Duchenne muscular dystrophy (DMD) and in gene therapies for limb-girdle muscular dystrophies (LGMDs), mucopolysaccharidosis type IIIA, Charcot-Marie-Tooth (CMT), and other CNS-related disorders, with more than 40 programs in various stages of development. The Company’s programs and research focus span several therapeutic modalities, including RNA, gene therapy and gene editing. For more information, please visit www.sarepta.com or follow us on Twitter, LinkedIn, Instagram and Facebook.
Internet Posting of Information
We routinely post information that may be important to investors in the 'Investors' section of our website at www.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us.
Source: Sarepta Therapeutics, Inc.
Sarepta Therapeutics, Inc.
Investors:
Ian Estepan, 617-274-4052, iestepan@sarepta.com
Media:
Tracy Sorrentino, 617-301-8566, tsorrentino@sarepta.com
FAQ
When will Sarepta Therapeutics report its fourth quarter and full-year 2020 financial results?
What time is the conference call for Sarepta Therapeutics' earnings?
How can I access the Sarepta Therapeutics conference call?
What is Sarepta Therapeutics' focus in genetic medicine?
Where can I find more information about Sarepta Therapeutics?
